ProCE Banner Activity

CME

From Congress to Clinic: A Post-ESMO Breast Cancer 2021 Update on Immune-Based Therapies in Triple-Negative Breast Cancer

Multimedia
Learn from the experts about the latest evidence on immune-based therapies in triple-negative breast cancer including checkpoint inhibitors and novel antibody-drug conjugates.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 02, 2021

Expiration: June 01, 2022

No longer available for credit.

Share

Faculty

Nadia Harbeck

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Ian E. Krop

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan individualized first-line treatment with immune checkpoint inhibitor–based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations using antibody–drug conjugates for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune-based therapies and combinations in patients with breast cancer
  • Appraise ongoing clinical trials assessing new immune-based approaches for appropriate patients with no biomarkers or those with HER2-low or HER3-high triple-negative breast cancer
  • Evaluate recently presented data as part of ESMO Breast 2021

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Nadia Harbeck, MD, PhD, has disclosed that she has received funds for lectures or consulting from AstraZeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, and Seattle Genetics.

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ian E. Krop, MD, PhD, has disclosed that he has received funds for research support from Pfizer and Genentech/Roche and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, MacroGenics, Merck, Novartis, and Pfizer.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, had no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 02, 2021, through June 01, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of triple-negative breast cancer.